Clinical trial · Observational
A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer
NCT06746298CI-TRIAL-00084042not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a prospective study of expression profiling-based assessment of the efficacy of neoadjuvant therapy for rectal cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoadjuvant Therapy | — | UNRESOLVED | — |
| Rectal Cancer | Malignant Rectal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Rectal cancer patients receiving neoadjuvant therapy
Primary outcomes (1)
- measure
- Objective Response Rate
- timeFrame
- From the start of the neoadjuvant therapy until just before surgery
- description
- The proportion of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST)
Secondary outcomes (3)
- measure
- Overall survival
- timeFrame
- 3 years
- description
- The time from the start of treatment to death due to any cause.
- measure
- Progression free survival
- timeFrame
- 3 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years, male or infertile female * Patients with rectal adenocarcinoma diagnosed by colonoscopic biopsy * Neoadjuvant therapy according to guideline recommendations * Endoscopic biopsy with access to biopsy tissue for subsequent RNA-seq testing * Patients who do not have a combination of primary malignant tumors elsewhere. * Patients who understand the purpose of the trial, participate voluntarily and sign an informed consent form. Exclusion Criteria: * Samples are not collected, stored, or processed in accordance with specified requirements * Sample does not meet the requirements for subsequent RNA-seq testing * Cases enrolled with a subsequent diagnosis other than rectal adenocarcinoma. * The patient refuses or is unable to complete the entire neoadjuvant treatment * Lack of post-neoadjuvant imaging results and lack of routine postoperative pathology results. * Other patients who, in the judgment of the investigator, do not meet the enrollment requirements
References
Publications (0)
Data not yet available
No reference posted for this study.